CME-certified Meeting Series

Inflammatory bowel disease (IBD) is a chronic, frequently progressive condition that affects approximately 1 to 1.3 million people in the United States. Substantial room for improvement in the care of patients with IBD is needed. The outcomes of patients with IBD are diminished by multiple factors, including uncertainty about approaches to diagnosis, assessment, and treatment, as well as a lack of knowledge about available therapies. To meet the persistent challenges associated with IBD management, health care professionals must be knowledgeable about the evidence-based and expert-recommended strategies for the treatment of patients with IBD. This unique continuing medical education program is designed to bring gastroenterologists and other health care professionals involved in the treatment of patients with IBD together with a nationally recognized faculty.


Featuring: Wheel of IBD Knowledge – Interactive gaming segment in which your team will partner with a faculty member to compete against your peers.

Saturday, October 27, 2018 – New York, NY
The Westin New York at Times Square
270 W 43rd St.
New York, NY
Saturday, December 1, 2018 – Newport Beach, CA
Newport Beach Marriott Hotel and Spa
900 Newport Center Dr.
Newport Beach, CA
8:00 am Introduction, Overview, and Pretest
8:15 am Redefining Disease Severity and Therapeutic Targets in UC and CD
8:40 am Treatment Considerations in the Newly Diagnosed IBD Patient
9:00 am IBD Dilemmas Panel Discussion – Optimizing Treatment in Mild to Moderate IBD
9:20 am Case Presentations: How Would You Treat?
9:50 am Posttest, Summary, and Question & Answer
10:00 am Break
10:15 am Understanding Biological Therapies in IBD
10:35 am Therapeutic Drug Monitoring to Optimize IBD Management
11:00 am Novel Therapeutic Targets for IBD – JAK Inhibitors
11:20 am Approaches to Disease Monitoring and De-escalation in IBD
11:45 am Wheel of Knowledge
12:05 pm Posttest, Summary, and Question & Answer
12:15 pm Conclusion

Slide to view agenda

Target Audience: The intended audience for the activities is gastroenterologists and other health care professionals involved in the treatment of patients with inflammatory bowel disease (IBD).

Learning Objectives: Upon successful completion of this activity, participants should be better able to:

  • Review current guidelines on treat-to-target approach in IBD.
  • Assess and monitor disease severity in patients with IBD, using evidence-based modalities that improve the care of established and new patients.
  • Select treatment strategies in mild to moderate IBD that safety deliver the appropriate therapy and improve patient outcomes.
  • Analyze the use of biologics, combination therapies, and emerging agents with novel mechanisms of action in patients with IBD refractory to current therapeutic options.
  • Incorporate the use of biomarkers, de-escalation of therapy, and other therapeutic regimens that may improve monitoring and mucosal healing in IBD.
  • Apply therapeutic drug monitoring as needed to optimize the management of IBD.

CME Information: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Gary R. Lichtenstein, MD
Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
Benjamin Cohen, MD, MAS
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Jean-Frederic Colombel, MD
Director of Feinstein IBD Clinical Center
& Helmsley Charitable Trust IBD Center
Icahn School of Medicine
Mount Sinai Hospital
New York, NY
Peter Higgins, MD, PhD, MSc
Associate Professor, Division of Gastroenterology
Director of IBD program
University of Michigan
University of Michigan
Ann Arbor, MI
Dermot McGovern, MD, FRCP, PhD
Director, Translational Medicine
Inflammatory Bowel Disease Center and Immunobiology Research Institute
Cedars-Sinai Medical Center
Associate Professor, Medicine
University of California, Los Angeles
David Geffen School of Medicine
Los Angeles, CA
Ellen Scherl, MD, FACP, FACG, AGAF, FASGE
Director, Jill Roberts Center for Inflammatory Bowel Disease
Jill Roberts Professor of Medicine
New York Presbyterian Hospital
Weill Cornell Medicine
Division of Gastroenterology and Hepatology
New York, NY
Ryan Ungaro, MD, MS
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY